ReviewVaccines2020
Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies.
Review in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- SARS-CoV-2 (COVID-19) vaccination in dermatology patients on immunomodulatory and biologic agents: Recommendations from the Australasian Medical Dermatology Group.The Australasian journal of dermatology · 2021Guideline
- Development and validation of a prediction model for the risk of relapse in psoriasis.Scientific reports · 2026Article
- Therapeutic Potential of Mesenchymal Stem Cells in Psoriasis.Cell biochemistry and biophysics · 2025Review
- Evaluation of T-Cell Responses Following Sequential Vaccination with PCV13 and PPSV23 AgainstVaccines · 2025Article
- Live vaccinations in dermatology for immunosuppressed patients: a narrative review.Archives of dermatological research · 2024Review
- Review
- Biologic drugs in hidradenitis suppurativa: what does the GP have to know? A narrative review.Frontiers in medicine · 2024Review
- COVID vaccine recommendations in dermatologic patients on immunosuppressive agents: Lessons learned from pandemic.Journal of cosmetic dermatology · 2022Review
- Article
- Low Pneumococcal Vaccination among Patients with Psoriasis in Germany: Results from Vac-Pso.Vaccines · 2022Article
- A severe case ofMedical mycology case reports · 2022Article
- SARS-CoV-2 vaccination and practical points in psoriasis patients: A narrative review.Dermatologic therapy · 2022Review
- Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review.Vaccines · 2022Review
- Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: A real life experience.Dermatologic therapy · 2022Article
- Recommendations for dermatologists treating patients with atopic dermatitis during the Covid-19 pandemic: a look into the past for a conscious vaccination management.Human vaccines & immunotherapeutics · 2021Review
- Vitamin D and COVID-19 in an immunocompromised patient with multiple comorbidities-A Case Report.Clinical case reports · 2021Article
- Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases.Vaccines · 2021Article
- Article
- Use of Methotrexate in the Treatment of Moderate to Severe Plaque Psoriasis in France: A Practice Survey.Clinical, cosmetic and investigational dermatology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic inflammatory skin disease usually treated with immunomodulatory/immunosuppressive agents. The use of these agents has been associated with an increased susceptibility to infections. Vaccination might represent a critical aspect in the management of patients with psoriasis treated with immunomodulatory/immunosuppressive therapies. This narrative review aimed to provide an overview on the immune response to vaccines in subjects treated with systemic agents used to treat patients with moderate to severe psoriasis. Publications appearing in PubMed, Scopus, and ISI-Web of Knowledge database were selected using Medical Subject Headings key terms. Overall, published data confirmed that vaccination with attenuated live vaccines during therapy with immunomodulatory/immunosuppressive therapies should be avoided. For nonlive vaccines, a more favorable safety profile of biologic agents compared to conventional systemic agents is described as the humoral response to vaccines is in general well-preserved. Treatment with cyclosporine and methotrexate is associated with lower antibody titers to vaccines, and thus these agents are better discontinued during vaccination. In contrast, treatment with biological agents is not associated with lower antibody response and can thus be continued safely.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.